Durable Overall Survival Benefit in Patients >= 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Ravandi, F; Ritchie, EK; Sayar, H; Lancet, JE; Craig, M; Vey, N; Strickland, SA; Schiller, GJ; Jabbour, EJ; Erba, HP; Pigneux, A; Horst, H-A; Recher, C; Klimek, VM; Cortes, JE; Roboz, GJ; Craig, AR; Ward, R; Smith, J; Kantarjian, HM; Stuart, RK

Published Date

  • December 2, 2016

Published In

Volume / Issue

  • 128 / 22

Published By


  • 8

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • San Diego, CA

Conference Start Date

  • December 3, 2016

Conference End Date

  • December 6, 2016